{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T09:46:46Z","timestamp":1648806406363},"reference-count":4,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1001\/jamapediatrics.2018.0772","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T12:49:04Z","timestamp":1525697344000},"page":"701","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy"],"prefix":"10.1001","volume":"172","author":[{"given":"Randal Charles","family":"Richardson","sequence":"first","affiliation":[{"name":"Gillette Children's Specialty Healthcare, St Paul, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"2","key":"ple180006r1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jamapediatrics.2017.4360","article-title":"Nusinersen for spinal muscular atrophy: are we paying too much for too little?","volume":"172","author":"Prasad","year":"2018","journal-title":"JAMA Pediatr"},{"key":"ple180006r2","unstructured":"Center for Drug Evaluation and Research; US Deptartment of Health and Human Services. Application number: 209531Origls000: medical reviews. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000MedR.pdf. Accessed January 9, 2018."},{"key":"ple180006r3","unstructured":"Center for Drug Evaluation and Research; US Deptartment of Health and Human Services. Application number: 209531Origls000: cross discipline team leader review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000CrossR.pdf. Accessed January 9, 2018."},{"key":"ple180006r4","unstructured":"Center for Drug Evaluation and Research; US Deptartment of Health and Human Services. Application number: 209531Origls000: office director memo. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000ODMemo.pdf. Accessed January 12, 2018."}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2680047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T13:41:56Z","timestamp":1530538916000},"score":1,"resource":{"primary":{"URL":"http:\/\/archpedi.jamanetwork.com\/article.aspx?doi=10.1001\/jamapediatrics.2018.0772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":4,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2018.0772","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,1]]}}}